Covered recipient · General Payments record
PRAVEEN KUMAR TUMULA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$6,258.84
11 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,052.50 | 4 |
| Food and Beverage | $206.34 | 7 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,700.89 | 2 |
| Janssen Global Services, LLC | $1,540.00 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,450.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,387.50 | 1 |
| Tempus AI, Inc | $56.25 | 1 |
| ABBVIE INC. | $54.70 | 2 |
| Regeneron Healthcare Solutions, Inc. | $38.57 | 1 |
| ADC THERAPEUTICS AMERICA, INC. | $19.32 | 1 |
| Merck Sharp & Dohme LLC | $11.61 | 1 |
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PRAVEEN KUMAR TUMULA
NPI 1447402896 · CMS profile ID 746364
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
AMARILLO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1447402896?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
11 matching records · $6,258.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–11 of 11.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $38.57 | 12/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213061261 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $19.32 | 11/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246115513 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,450.00 | 10/30/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223786660 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.89 | 09/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207193025 | CMS |
| Merck Sharp & Dohme LLC | $11.61 | 09/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238159807 | CMS |
| Tempus AI, Inc | $56.25 | 09/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250352686 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,675.00 | 06/03/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207201742 | CMS |
| ABBVIE INC. | $28.89 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204584505 | CMS |
| Janssen Global Services, LLC | $1,540.00 | 03/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1173805813 | CMS |
| Janssen Scientific Affairs, LLC | $1,387.50 | 03/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174194990 | CMS |
| ABBVIE INC. | $25.81 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204584501 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $604,557.82 | 36 |
| PY2024 | Principal investigator | $1,085,444.24 | 161 |
| PY2023 | Principal investigator | $684,815.25 | 77 |
| PY2022 | Principal investigator | $638,195.90 | 127 |
| PY2021 | Principal investigator | $416,830.90 | 164 |
| PY2020 | Principal investigator | $201,522.62 | 122 |
| PY2019 | Recipient | $1,287.72 | 1 |
| PY2019 | Principal investigator | $54,363.67 | 98 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $4,998.00 | 12/05/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211681158 |
| Principal investigator 1 | Genentech, Inc. | $4,998.00 | 12/05/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211681164 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,220.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335087 |
| Principal investigator 1 | BeOne Medicines Ltd. | $8,702.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335092 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,220.00 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335100 |
| Principal investigator 1 | BeOne Medicines Ltd. | $497.06 | 11/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335104 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,881.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235993799 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 11/18/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335096 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 11/18/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335108 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 11/18/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335114 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 11/18/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335117 |
| Principal investigator 1 | Epizyme, Inc. | $1,125.00 | 11/05/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281610 |
| Principal investigator 1 | Genentech, Inc. | $1,125.00 | 11/03/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211681116 |
| Principal investigator 1 | Genentech, Inc. | $1,125.00 | 11/03/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211681134 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335121 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 10/28/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190335126 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $985.00 | 10/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190302071 |
| Principal investigator 1 | Epizyme, Inc. | $1,125.00 | 09/04/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184281478 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $103.50 | 09/03/2025 | Non-covered Recipient Entity Us Oncology Research | A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma | No dispute reported | 06/30/2026 | 1235992121 |
| Principal investigator 1 | Genentech, Inc. | $2,594.00 | 07/11/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211680321 |
| Principal investigator 1 | Genentech, Inc. | $1,125.00 | 07/09/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211680295 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,125.00 | 06/17/2025 | Non-covered Recipient Entity Texas Oncology-Amarillo Cancer Center | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190331319 |
| Principal investigator 1 | Celgene Corporation | $7,120.00 | 05/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute Llc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1222306847 |
| Principal investigator 1 | Genentech, Inc. | $1,125.00 | 04/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211679983 |
| Principal investigator 1 | Genentech, Inc. | $1,125.00 | 04/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211680003 |
| Principal investigator 1 | Genentech, Inc. | $1,125.00 | 04/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211680051 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,317.00 | 04/15/2025 | Non-covered Recipient Entity Texas Onco Southwest Fort Worth | Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions | No dispute reported | 06/30/2026 | 1235993245 |
| Principal investigator 1 | Celgene Corporation | $375.00 | 04/09/2025 | Non-covered Recipient Entity Texas Onco Southwest Fort Worth | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. | No dispute reported | 06/30/2026 | 1222304639 |
| Principal investigator 1 | Celgene Corporation | $59,284.00 | 04/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1222305468 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $83,641.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions | No dispute reported | 06/30/2026 | 1235993797 |
| Principal investigator 1 | Genentech, Inc. | $17,750.00 | 04/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211679977 |
| Principal investigator 1 | Genentech, Inc. | $70.00 | 04/01/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211680237 |
| Principal investigator 1 | Genentech, Inc. | $1,297.00 | 01/22/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211679899 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $19,519.00 | 01/15/2025 | Non-covered Recipient Entity Texas Onco Southwest Fort Worth | Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions | No dispute reported | 06/30/2026 | 1235993243 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,662.98 | 01/15/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190302069 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $334,448.28 | 01/09/2025 | Non-covered Recipient Entity TEXAS ONCO AMARILLO | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | No dispute reported | 06/30/2026 | 1190298308 |